Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Imunon, Inc.

  • LAWRENCEVILLE, New Jersey
  • Public · NASDAQ: IMNN
  • 20 employees
$8.7MMarket cap
$500.0KRevenue · FY2022
-$14.5MNet income
20Employees
IMNNNASDAQ
1995IPO

About Imunon, Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2022
$500.0K
Net income
-$14.5M
Total assets
$12.3M
Market cap
$8.7M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: IMNN

15-minute delayed · data by Polygon.io

Market cap
$8.7M
Open
Day range
Prev close
Volume
IPO date
Jul 24, 1995

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Imunon, Inc..

Write a review
Explore

Similar companies

Browse all →